Table 3.
Treatment ranking (% probability) and SUCRA values based on overall survival results
| AAP | Doc | ZA + Doc | ZA + Cel | ZA | Cel | ADT alone | |
|---|---|---|---|---|---|---|---|
| Best | 94.2 | 0.7 | 1.3 | 3.8 | 0.0 | 0.0 | 0.0 |
| Second best | 5.3 | 34.9 | 25.5 | 33.0 | 0.3 | 1.0 | 0.0 |
| Third best | 0.4 | 36.8 | 30.3 | 27.0 | 2.4 | 3.1 | 0.0 |
| Fourth best | 0.1 | 23.6 | 30.8 | 23.9 | 12.2 | 9.3 | 0.1 |
| Fifth best | 0.0 | 3.8 | 9.3 | 9.3 | 48.7 | 26.0 | 2.9 |
| Sixth best | 0.0 | 0.2 | 2.6 | 2.5 | 31.3 | 33.6 | 29.8 |
| Worst | 0.0 | 0.0 | 0.2 | 0.5 | 5.1 | 27.0 | 67.2 |
| SUCRA | 1.0 | 0.7 | 0.6 | 0.6 | 0.3 | 0.2 | 0.1 |
AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-deprivation therapy; Cel, celecoxib; Doc, docetaxel; SUCRA, surface under the cumulative rank; ZA, zoledronic acid.